The GIFT Nifty futures, which are an early indicator of the Nifty50 index stocks, were trading higher by 32 points at 25,740, indicating that the domestic benchmark indices are likely to make a positive start on Thursday. 

Earlier on Tuesday, 4 November, the Domestic benchmark indices S&P BSE Sensex slipped by 519 points or 0.62%, and settled at 83,459, while the Nifty50 traded 0.64% higher or 166 points, closing at 25,598.

Here are some stocks that are likely to remain in focus on 6 November.

Quarterly Results Today: Life Insurance Corporation of India, ABB India, Ola Electric Mobility, Apollo Hospitals Enterprise, Lupin, UPL, Zydus Lifesciences, Abbott India, Aster DM Healthcare, Cholamandalam Investment and Finance Company, Amber Enterprises India, Amara Raja Energy & Mobility, Crompton Greaves Consumer Electricals, Cummins India, Godrej Properties, Mankind Pharma, Multi Commodity Exchange of India, and Smartworks Coworking Spaces are some of the prominent companies set to announce their quarterly earnings for July-September.

Adani Energy Solutions: Adani Energy Solutions signed an agreement with RSWM to supply 60 MW of renewable energy to RSWM’s multiple manufacturing sites. Under the Group Captive Scheme, RSWM invested Rs 60 crore in a renewable generation company to secure 31.53 crore units of green power annually for its plants across Rajasthan. With this initiative, renewable energy’s share in RSWM’s total consumption will rise from 33% to 70%, significantly advancing its sustainability goals.

Zydus Lifesciences: Zydus Lifesciences received an Establishment Inspection Report (EIR) from the USFDA for its SEZ II manufacturing facility in Ahmedabad, following a Pre-Approval Inspection (PAI) conducted from August 11–14, 2025. The USFDA classified the site as “No Action Indicated (NAI)”, confirming that the inspection closed without any observations, reinforcing Zydus’s track record of regulatory compliance and quality excellence.

Tata Consultancy Services: Tata Consultancy Services (TCS) expanded its 18-year strategic partnership with ABB to modernise the company’s global hosting operations, simplify its IT infrastructure, and strengthen its digital backbone. The collaboration aims to boost resilience, efficiency, and innovation across ABB’s worldwide operations.

Marksans Pharma: Marksans Pharma’s UK-based subsidiary, Relonchem, secured marketing authorisation from the UK MHRA for its Exemestane 25 mg film-coated tablets, a treatment for hormone-positive breast cancer in postmenopausal women. The approval strengthens Marksans’s oncology portfolio and expands its presence in the UK pharmaceutical market.

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!